
Colorectal cancer is the second commonest cancer worldwide, with 1.7 million diagnoses annually. Surgical resection followed by chemotherapy is the treatment of choice for colon cancer.
A clinical trial has provided information on the effectiveness of preoperative chemotherapy in treating operable colon cancer. This trial offers promising insights into a potential new approach to improve outcomes for patients with colon cancer.
Colon Cancer
Colon cancer, also known as colorectal cancer, is a type of cancer that affects the large intestine (colon) or rectum. It is one of the most common types of cancer worldwide and can be life-threatening if not diagnosed and treated in its early stages.
Traditionally, surgery has been the primary treatment for operable colon cancer. This involves removing the tumor and nearby lymph nodes. While surgery can be successful, there is still a risk of cancer recurrence, especially if the disease has spread beyond the colon. Hence, postoperative chemotherapy was added to the management. However, despite adjuvant chemotherapy, 20%-30% of patients still develop recurrent disease that is usually incurable.
Preoperative or neoadjuvant chemotherapy (NAC) has substantially improved outcomes in other gastrointestinal cancers and may have potential advantages over postoperative chemotherapy in colon cancer, but this requires formal evaluation.
Clinical Trial
The clinical trial has examined the use of preoperative chemotherapy, which involves administering anti-cancer drugs before surgery. The goal is to shrink the tumor, potentially making it easier to remove during surgery and reducing the risk of cancer cells spreading.
The research team conducted a clinical trial involving 1053 patients with locally advanced colon cancer. The participants were divided into two groups randomly. One group received preoperative chemotherapy followed by surgery and postoperative chemotherapy, while the other group received surgery with postoperative chemotherapy only. The primary endpoint was residual disease or recurrence within 2 years. Secondary outcomes included surgical morbidity, histopathologic stage, regression grade, completeness of resection, and cause-specific mortality.